bluebird bio Announces September Investor Events Read more about bluebird bio Announces September Investor Events
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions Read more about FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy Read more about FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
bluebird bio stock trading halted today June 9th and tomorrow June 10th Read more about bluebird bio stock trading halted today June 9th and tomorrow June 10th
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting Read more about bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
bluebird bio at Goldman Sachs 43rd Annual Global Healthcare Conference Read more about bluebird bio at Goldman Sachs 43rd Annual Global Healthcare Conference